NCT01540253View on ClinicalTrials.gov

PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2016

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

PI3K inhibitor BKM120

Given PO

DRUG

docetaxel

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

questionnaire administration

Ancillary studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER

NCT01540253 - PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic | Biotech Hunter | Biotech Hunter